Product Images Imatinib Mesylate
View Photos of Packaging, Labels & Appearance
- 100 mg Imatinib Mesylate Tablet Blister - 100 mg Imatinib Mesylate Tablet Blister
- 100 mg Imatinib Mesylate Tablets Carton - 100 mg Imatinib Mesylate Tablets Carton
- AHP88221
- Figure 1: Progression Free Survival (ITT Principle) - Figure1
- Figure 2: Time to Progression to AP or BC (ITT Principle) - Figure2
- Figure 3: Study 1 Recurrence-Free Survival (ITT Population) - Figure3
- Figure 4: Study 2 Recurrence-Free Survival (ITT Population) - Figure4
- Figure 5: Study 2 Overall Survival (ITT Population) - Figure5
- Structural Formula - Structural Formula
Product Label Images
The following 9 images provide visual information about the product associated with Imatinib Mesylate NDC 60687-882 by American Health Packaging, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
100 mg Imatinib Mesylate Tablet Blister - 100 mg Imatinib Mesylate Tablet Blister
100 mg Imatinib Mesylate Tablets Carton - 100 mg Imatinib Mesylate Tablets Carton
This text provides detailed information about Imatinib Mesylate tablets, with NDC 60687-882-21. Each tablet contains 118.6 mg of Imatinib Mesylate. The usual dosage should be determined based on prescribing information. These tablets should be stored at 20-25°C (68-77°F) with excursions permitted between 15-30°C (53-66°F). The product should be protected from moisture. It is essential not to use the tablets if the packaging is torn or broken. The product was distributed by American Health Packaging in Columbus, Ohio.*
AHP88221
Figure 1: Progression Free Survival (ITT Principle) - Figure1
This data appears to be related to a clinical trial involving Imatinib Mesylate and IFN+Ara-C arms, assessing the progression of patents. The hazard ratio is calculated to be 0.378 (CI: 0.291-0.493) with a significant p-value of <0.0001 from the Log-rank Test. Progression status is delineated based on censoring at discontinuation and last follow-up. The graph shows the trend in months since randomization.*
Figure 2: Time to Progression to AP or BC (ITT Principle) - Figure2
Available data shows that there were 35 patients who progressed to accelerated phase (AP) or blast crisis (BC), while 137 patients were censored at discontinuation and 381 were censored at fast follow-up. The Hazard Ratio [95% CI] indicates a significant difference between the Imatinib Mesylate Arm and the IFN+Ara-C arm. The hazard ratio is 0.474 with a confidence interval of [0.312, 0.722], and the Log-rank Test P-value is less than 0.001. The data spans over 60 months since randomization.*
Figure 3: Study 1 Recurrence-Free Survival (ITT Population) - Figure3
This text appears to be related to a medical study evaluating the probability of being alive and recurrence-free for patients taking Imatinib 400mg versus a placebo. The data includes the number of patients at risk and the survival time in months. The study involves a comparison between the two groups, Imatinib and Placebo, showing different numbers of patients and their corresponding survival times.*
Figure 4: Study 2 Recurrence-Free Survival (ITT Population) - Figure4
This is not available.*
Figure 5: Study 2 Overall Survival (ITT Population) - Figure5
Structural Formula - Structural Formula
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
